Vincerx Inc【VINC】株式ニュース | ADVFN

US Dollar vs Yen

登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。

登録

Vincerx Inc (VINC)

0.252

-0.004

(-1.56%)

終了 11月23日 6:00AM

0.2531

0.0011

(0.44%)

取引時間後: 9:40AM

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

Form 8-K - Current report

Vincerx Pharma Reports Third Quarter 2024 Financial Results

Continued enrollment and dose escalation in Phase 1 study of VIP943, a potentially best-in-class anti-CD123...

Form PRE 14A - Other preliminary proxy statements

Vincerx Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate Updates

VIP943 demonstrates promising safety and tolerability and achieves two complete responses to date in Phase 1...

Form SC TO-I/A - Tender offer statement by Issuer: [Amend]

Form SC TO-I/A - Tender offer statement by Issuer: [Amend]

Form SC TO-I/A - Tender offer statement by Issuer: [Amend]

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form SC TO-I - Tender offer statement by Issuer

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Vincerx Pharma Reports Second Quarter 2024 Financial Results

Vincerx continues to enroll its Phase 1 studies of antibody-drug conjugate (ADC) VIP943, with data expected by...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

tw0122

VINC .84 + 20% …05:05 PM EDT, 10/07/2024 (MT Newswires) -- Vincerx Pharma (VINC) said its VIP943 leukemia drug showed "promising safety and tolerability," achieving two complete responses to date in a phase 1 dose-escalation study

The VIP943 antibody-drug conjugate is being evaluated in relapsed/refractory acute myeloid leukemia, higher-risk myelodysplastic syndrome and B-cell acute lymphoblastic leukemia, the company said Monday in a statement.

Another data update is expected by the end of the year, the company said.

In an update on VIP236 being evaluated in a first-in-human, phase 1 dose-escalation study as a monotherapy in patients with advanced solid tumors, the company said it intends to pursue a strategic partner to "champion its future development" in order to focus on VIP943.

Vincerx expects a cash runway into early 2025.

Shares of the company jumped 15% in after-hours activity.

Price: 0.8000, Change: +0.10, Percent Change: +

Laster

What a cluster this stock has become.
Unreal actually. $0.60 to $10 back to $0.60 all within 4 months.
Can’t believe they didn’t try to do the financing when it was trading above $5.

RAlbert

RAlbert 7月前

Tomorrow will be $1.50

RAlbert

RAlbert 7月前

No news on dilution yet. When will we see a rebound? Seeking money being lost is the painful part of life

RAlbert

RAlbert 7月前

Blood bath. I should have waited one more day.

Monksdream

Monksdream 7月前

Somebody knows something you don’t

RAlbert

RAlbert 7月前

I don’t find the price and volume the capital raise is. Am I missing anything here?

Monksdream

Monksdream 7月前

Check for SEC filings

RAlbert

RAlbert 7月前

Is the capital raise 80% discounted to yesterday price? Insane

Monksdream

Monksdream 7月前

Check for a capital raise which means dilution

RAlbert

RAlbert 7月前

Wonder why there is a steep fall in price when the results are not negative.

RAlbert

RAlbert 7月前

Wonder why there is a steep fall in price when the results are not negative.

Monksdream

Monksdream 8月前

VINC 10Q due 4/3

Monksdream

Monksdream 8月前

VINC 10Q due 3/25
Next day settlement 5/28 per SEC mandate

Monksdream

Monksdream 9月前

VINC new 52.week hi

Monksdream

Monksdream 9月前

VINC new 52 week high

Monksdream

Monksdream 9月前

VINC in the Barchart Top 10
https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc

Tom turtles

Tom turtles 9月前

Very nice surprise...🆙⬆️

Monksdream

Monksdream 9月前

VINC new 52 week high

glenn1919

glenn1919 9月前

VINC..................................https://stockcharts.com/h-sc/ui?s=VINC&p=W&b=5&g=0&id=p86431144783

Awl416

160k wall getting gobbled up

Awl416

Another leg. Damn

Awl416

Who’s poking it?

Monksdream

Monksdream 9月前

make it happen

make it happen 10月前

It's deficient. Failed to meet NASDAQs listing requirements. I'm expecting a reverse split in the future.

alchemytrader

alchemytrader 11月前

Monksdream

Monksdream 1年前

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約